Explore

New Imaging Method Links Tumor Cell Spatial Organization to Cancer Outcomes

New Imaging Method Links Tumor Cell Spatial Organization to Cancer Outcomes

A doctoral thesis by Linglong Huang at the Karolinska Institutet's Department of Oncology-Pathology has introduced a new imaging method that connects the spatial organization of cells within solid tumors to patient outcomes. This method analyzes tissue images without requiring the precise definition of cell boundaries, which is often challenging for irregularly shaped cells like fibroblasts. The research indicates that the arrangement of cells in the tumor microenvironment, including immune cells and other support cells, provides clinically relevant information. For instance, specific patterns of macrophages dispersing from blood vessels were linked to shorter survival. The study also found that how closely cells are packed together in a tumor correlates with patterns of gene activity, with densely packed regions showing higher activity in pathways related to mechanical forces and a particular type of memory T cell. This suggests that the physical structure of a tumor can offer insights into biological pro...

Precision Medicine Platform Targets Acute Myeloid Leukemia with Personalized Therapies

Precision Medicine Platform Targets Acute Myeloid Leukemia with Personalized Therapies

A new research project, funded by IFAB and coordinated by Professor Giovanni Roti of the University of Parma, is developing a functional precision medicine platform to treat acute myeloid leukemia (AML). This initiative aims to move beyond conventional, often ineffective, treatments for AML, particularly in elderly patients. The project focuses on the individual variability of the disease, recognizing that cancer manifests differently in each patient. Researchers are utilizing advanced algorithms to test hundreds of non-commercialized pharmacological molecules on individual cancer cells. This approach significantly expands the scope of drug testing compared to the standard pool of about 15 drugs currently used for AML. The ultimate goal is to identify personalized therapeutic profiles that are more effective and can treat a larger percentage of patients who are currently considered untreatable. The project seeks to shift the paradigm from a one-size-fits-all treatment to therapies tailored to specific dise...

ASAC Trial Finds Aspirin Ineffective for Preventing Recurrence in Metastatic Colorectal Cancer Patients

ASAC Trial Finds Aspirin Ineffective for Preventing Recurrence in Metastatic Colorectal Cancer Patients

The Scandinavian ASAC trial, a randomized, double-blind, placebo-controlled phase 3 study, has concluded that aspirin does not reduce the risk of recurrence or death in patients who have undergone curative-intent treatment for colorectal cancer liver metastases. Conducted across 14 hospitals in Norway, Sweden, and Denmark, the trial involved 428 patients who received either 160 mg of aspirin daily or a placebo after surgical resection and/or ablation of their liver metastases. The primary endpoint, disease-free survival, showed no significant difference between the aspirin and placebo groups, with median disease-free survival at 1.13 years and 1.40 years, respectively. While a secondary endpoint of overall survival showed a statistically significant difference favoring the placebo group (84.9% vs. 75.7% in the aspirin group after three years), the trial was not primarily designed to assess overall survival, and detailed data on post-recurrence treatments were not collected, necessitating cautious interpret...

Privo Technologies Announces 95.5% Complete Response Rate for Non-Surgical Oral Cancer Therapy PRV111 in Phase 2 Trial

Privo Technologies Announces 95.5% Complete Response Rate for Non-Surgical Oral Cancer Therapy PRV111 in Phase 2 Trial

Privo Technologies has announced positive results from its CLN-004 Phase 2 trial for PRV111, a nanoengineered, cisplatin-releasing patch designed to treat non-invasive oral cancer and high-grade dysplasia. The study, conducted at four major U.S. hospitals, involved 22 patients with biopsy-confirmed conditions. Twenty-one of these patients (95.5%) achieved a centrally confirmed pathologic complete response, meaning no residual dysplastic cells were found after treatment. The remaining patient was downstaged to low-grade dysplasia. Crucially, all 22 patients avoided the need for standard-of-care surgery, with treated lesions resolving and mucosal surfaces regenerating without scarring or distortion. At a median follow-up of 14 months, no recurrences were observed, and some patients have maintained responses for over 21 months. The treatment was well-tolerated, with negligible systemic cisplatin exposure and primarily mild, transient oral symptoms reported as treatment-related adverse events.

Savannah Morning News

Melissa Olsen faced breast cancer during the pandemic

Melissa Olsen faced breast cancer during the pandemic

Melissa Olsen was diagnosed with breast cancer as the pandemic began. She shares her story of early detection.

Palm Beach Post

Breast cancer survivors needed for FAU research study

Breast cancer survivors needed for FAU research study

The study will examine whether supervised aerobic exercise, with or without non-invasive brain stimulation, can improve memory, concentration, and focus following cancer treatment.

Regeneron Seeks Principal Scientist for Precision Medicine in Tarrytown, New York

Regeneron Seeks Principal Scientist for Precision Medicine in Tarrytown, New York

Regeneron Seeks Principal Scientist for Precision Medicine in Tarrytown, New York

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

Diabetes Management Critical for Patients Undergoing Targeted Cancer Therapy

Diabetes Management Critical for Patients Undergoing Targeted Cancer Therapy

Patients with diabetes who are undergoing targeted cancer therapy require heightened monitoring and careful management of their blood sugar levels. Certain targeted therapies, specifically mTOR inhibitors and PI3K inhibitors, are known to directly interfere with the body's insulin and glucose management pathways, leading to raised blood sugar. National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) guidelines for these drug classes explicitly recommend glucose monitoring and management. While other targeted therapies may have less predictable effects on blood sugar, any new cancer treatment can alter how a patient's diabetes responds. Therefore, close collaboration between the oncologist and diabetes specialist is essential from the beginning of treatment, rather than as an afterthought once blood sugar readings begin to change. Having diabetes does not preclude a patient from receiving targeted therapy; instead, it necessitates a coordinated approach to manage both co...

Researchers Identify GNG4 Gene as Key Driver of Immune Exclusion in Liver Cancer, Hindering Immunotherapy Effectiveness

Researchers Identify GNG4 Gene as Key Driver of Immune Exclusion in Liver Cancer, Hindering Immunotherapy Effectiveness

A new study published in the Journal of Translational Medicine has identified the GNG4 gene as a significant factor in the failure of immunotherapies for hepatocellular carcinoma, the most common form of liver cancer. The research, conducted by a team including Xiangchou Yang, Yi Xu, and Chenwei Pan across various institutions, found that high expression of GNG4 in malignant liver cells creates a molecular barrier that actively prevents CD8-positive T cells from infiltrating tumors. These T cells are crucial for the immune system's ability to destroy cancer cells. The study utilized a comprehensive approach, combining single-cell RNA sequencing, spatial transcriptomics, and multiplex immunofluorescence to understand the gene's role and location within the tumor architecture. GNG4 expression was found to be concentrated in areas of tumors that did not respond to neoadjuvant immunotherapy, and its presence was strongly linked to poor patient prognosis. When GNG4 was silenced in laboratory settings, cancer ce...

Lenvatinib Treatment: Dispelling Myths on Dose Cuts and Side Effects in Cancer Therapy

Lenvatinib Treatment: Dispelling Myths on Dose Cuts and Side Effects in Cancer Therapy

Common misconceptions surrounding lenvatinib, a targeted cancer therapy, are being addressed to clarify its mechanism and patient experience. Many patients mistakenly believe that a dose reduction indicates the drug is no longer effective. However, dose modifications are a standard part of the lenvatinib protocol, designed to manage side effects and allow patients to sustain treatment over time. The initial high dose is intended to maximize early activity, and subsequent reductions aim to find a tolerable level. Another prevalent myth is that side effects, such as high blood pressure, fatigue, or hand-foot soreness, signify worsening cancer. These side effects are actually a result of the drug's action on healthy tissues and blood vessels, not an indicator of tumor progression. Furthermore, lenvatinib is often incorrectly categorized as chemotherapy. It is, in fact, a tyrosine kinase inhibitor, a type of targeted therapy that specifically blocks proteins tumors need for growth and blood vessel formation, d...

Karolinska Institutet Team Advances Precision Oncology Through Multi-Omics Data Integration

Karolinska Institutet Team Advances Precision Oncology Through Multi-Omics Data Integration

The Cancer Bioinformatics team, led by Nick Tobin at the Karolinska Institutet, is actively integrating multi-omics, single-cell, and spatial transcriptomic data with clinical and pathological information to enhance precision oncology, particularly in breast cancer. Their research employs AI-driven computational approaches to analyze large-scale molecular datasets. The primary goal is to investigate tumor heterogeneity, tumor microenvironment interactions, and biomarker development, as well as aging-related changes in cancer biology. While their main focus is on breast cancer, the team also utilizes extensive pan-cancer datasets to identify shared biological principles across various tumor types. A central objective is to determine when molecular information can provide clinically meaningful insights beyond established pathological and clinical markers.